NCT00036075已完成2 期
Study Using CP-461 to Treat Advanced Prostate Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 2
研究概览
简要总结
The purpose of this study is to investigate whether an investigational drug, CP-461, is safe and effective for the treatment of patients with prostate cancer and who have measurable disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Eligibility Criteria:
- •Male 18 years of age.
- •Histologically confirmed adenocarcinoma of the prostate, stage D1 or D
- •Failure of androgen ablation (orchiectomy or LHRH, flutamide).
- •Patients must have PSA progression and progression in measurable disease.
- •No prior history of systemic chemotherapy.
- •No investigational drugs within 4 weeks of study entry.
- •No radiation therapy or hormonal therapy within 4 weeks of study entry.
- •No isotope therapy within 6 weeks of study entry.
- •No antiandrogens within 4 weeks of study entry. Patients must continue LHRH.
- •If patients had prior surgery, it must be at least 21 days prior to study entry, and the patient must have recovered from all side effects.
- •Patients must have stopped bisphosphonates 28 days prior to study entry.
- •No prior malignancy allowed except for adequately treated basal cell or squamous cell skin cancer, or adequately treated stage I or II cancer from which the patient is currently in remission, and has been disease free for at least 5 years.
- •Patients must have recovered from major infections and/or surgical procedures, and in the opinion of the investigator not have significant active concurrent medical illness, such as a history of significant neurologic or psychiatric disorders including psychotic disorders, dementia, or seizures that would preclude protocol treatment or survival.
- •All patients must be informed of the investigational nature of the study and must sign and give written informed consent in accordance with institutional and federal guidelines.
- •No other chemotherapeutic, biological response modifiers, radiation therapy, corticosteroid therapy, or hormonal concomitant therapy (except continuation of LHRH) may be given during treatment. Patients should not be planning on receiving concomitant bisphosphonates.
- •ECOG Performance Status = 0-
- •WBC > or = 3500/ul or ANC > or = 1500/ul.
- •Bilirubin < or = ULN.
- •Creatinine < or = 2.0 mg/dl.
- •Platelets > or = 100,000/ul.
- •ALT or AST < 2.5 X ULN.
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Study of CP-461 in Patients With Advanced Renal Cell CancerRenal Cell CarcinomaNCT00036036Astellas Pharma Inc14
尚未招募
不适用
Evaluation of safety and efficacy in prostate cancer patients treated with focal low-dose-rate brachytherapyProstate cancerJPRN-UMIN000030509Kitasato University School of Medicine, Department of Urology20
终止
2 期
CP-461 in the Treatment of Patients With Advanced MelanomaMalignant MelanomaNCT00060710Astellas Pharma Inc35
已完成
1 期
Vaccination in Prostate Cancer (VANCE)Prostate CancerNCT02390063University of Oxford40
终止
1 期
Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPCMetastatic Castration-resistant Prostate CancerProstate CancerNCT03792841Amgen212